Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Accounts Payables (2020 - 2025)

Biofrontera has reported Accounts Payables over the past 6 years, most recently at $4.9 million for Q4 2025.

  • Quarterly results put Accounts Payables at $4.9 million for Q4 2025, up 14.6% from a year ago — trailing twelve months through Dec 2025 was $4.9 million (up 14.6% YoY), and the annual figure for FY2025 was $4.9 million, up 14.6%.
  • Accounts Payables for Q4 2025 was $4.9 million at Biofrontera, down from $6.6 million in the prior quarter.
  • Over the last five years, Accounts Payables for BFRIW hit a ceiling of $11.0 million in Q3 2023 and a floor of $269000.0 in Q1 2022.
  • Median Accounts Payables over the past 5 years was $4.5 million (2023), compared with a mean of $4.8 million.
  • Biggest five-year swings in Accounts Payables: skyrocketed 1551.06% in 2022 and later tumbled 58.7% in 2023.
  • Biofrontera's Accounts Payables stood at $658000.0 in 2021, then skyrocketed by 1551.06% to $10.9 million in 2022, then tumbled by 58.7% to $4.5 million in 2023, then dropped by 4.77% to $4.3 million in 2024, then grew by 14.6% to $4.9 million in 2025.
  • The last three reported values for Accounts Payables were $4.9 million (Q4 2025), $6.6 million (Q3 2025), and $5.8 million (Q2 2025) per Business Quant data.